Efficacy and safety of single or combine using radionuclide 89SrCl2/Yunke in cancer patients with bone me-tastasis
10.3969/j.issn.1006-5725.2017.17.013
- VernacularTitle:联合应用放射性核素89SrCl2与云克治疗肿瘤骨转移疗效
- Author:
Yu HUANG
1
;
Ren JING
;
Linghui PAN
Author Information
1. 广西医科大学附属肿瘤医院麻醉科
- Keywords:
radionuclide 89SrCl2;
Yunke;
combined therapy;
cancer with bone metastasis
- From:
The Journal of Practical Medicine
2017;33(17):2857-2860
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of single or combine using radionuclide 89SrCl2/Yunke in cancer patients with bone metastasis. Methods Four hundred and one cancer patients with bone metas-tasis during 2012 Jan to 2016 Jan in Affiliated Tumor Hospital of Guangxi Medical University were included by a prospective study. According to different therapy ,these patients were randomly divided into three groups:radionu-clide 89SrCl2 group(n=111),Yunke group(n=130)and combined therapy group(n=160). The effect of pain relief and adverse reaction among three groups were compared after therapy. Results Compared with single using radionuclide 89SrCl2 or Yunke ,the cancer pain and bone metastasis in combined-using group were significantly re-lieved with effective rate of 91.25%and 98.75%respectively;the incidence of'pain shine'(11.7%),leucopenia (10.8%)and thrombocytopenia(6.3%)in combined-using group were both lower than single-using group. The ef-fective rate of cancer pain and bone metastasis relief ,and incidence of adverse reaction among single using radionu-clide 89SrCl2 or Yunke were similar. Conclusion Combined-using radionuclide 89SrCl2 and Yunke would effectively and safely relieve cancer with bone metastasis.
